LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

29.88

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.5

Max

30.57

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-10M -67M
Pelno marža	-7,753.425
Darbuotojai	186
EBITDA	-9.8M -73M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+78% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	111M 1.6B
Ankstesnė atidarymo kaina	29.88
Ankstesnė uždarymo kaina	29.88

Naujienos nuotaikos

By Acuity

50%

155 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-02 23:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2026-03-02 23:37; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2026-03-02 23:26; UTC

Svarbiausios naujienos

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2026-03-02 22:41; UTC

Rinkos pokalbiai

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2026-03-02 22:32; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-02 22:32; UTC

Rinkos pokalbiai

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2026-03-02 22:21; UTC

Rinkos pokalbiai

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2026-03-02 22:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-02 22:11; UTC

Rinkos pokalbiai

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2026-03-02 22:10; UTC

Įsigijimai, susijungimai, perėmimai

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2026-03-02 22:06; UTC

Rinkos pokalbiai

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2026-03-02 22:00; UTC

Rinkos pokalbiai

Uždarbis

Global Forex and Fixed Income Roundup: Market Talk

2026-03-02 22:00; UTC

Rinkos pokalbiai

Uždarbis

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2026-03-02 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Energy & Utilities Roundup: Market Talk

2026-03-02 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-02 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-02 21:35; UTC

Įsigijimai, susijungimai, perėmimai

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2026-03-02 21:34; UTC

Įsigijimai, susijungimai, perėmimai

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2026-03-02 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026-03-02 21:17; UTC

Svarbiausios naujienos

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2026-03-02 20:44; UTC

Uždarbis

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026-03-02 20:43; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2026-03-02 20:28; UTC

Uždarbis

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2026-03-02 20:25; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2026-03-02 20:24; UTC

Uždarbis

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026-03-02 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026-03-02 20:12; UTC

Svarbiausios naujienos

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2026-03-02 20:08; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-02 20:08; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2026-03-02 20:05; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

78% į viršų

12 mėnesių prognozė

Vidutinis 53.56 USD 78%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

155 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.